Mycoplasma belongs to a genus of bacteria that lack a cell wall, and it is currently considered the smallest known cell at about 0.1 microns in diameter. This characteristic makes them naturally defiant to antibiotics that target cell wall synthesis. It can be parasitic or saprotrophic. Several variants are pathogenic in humans, including M. Pneumoniae, which is a relevant cause of “walking” pneumonia and other respiratory disorders, and M. Genitalium is believed to be involved in pelvic inflammatory diseases, and also their infections in humans are associated with skin eruptions in 17% of cases. Mycoplasma species are the nano bacterial cells yet discovered, can survive without oxygen, and come in various shapes. Their varients are often found in research laboratories as contaminants in cell culture. Mycoplasma cell culture contamination occurs due to contamination from individuals or contaminated cell culture element ingredients. Mycoplasma may induce cellular changes, including chromosome aberrations, changes in metabolism, and cell growth. Severe Mycoplasma infections may destroy a cell line. Detection techniques include DNA probe, enzyme immunoassays, PCR, plating on sensitive agar, and staining with a DNA stain.
The global mycoplasma market size is projected to grow at a CAGR of over 12.54% during 2020–2027. Mycoplasmas are known as the “crabgrass” of cell cultures because their infections are persistent, frequently difficult to detect, diagnose or cure. Contamination of cell cultures by mycoplasmas constitutes major problems in biotechnological industries, research laboratories, and for cell culturists as these bacterial strains are a common cause of cell line contamination affecting roughly 15-35% of cell cultures. Therefore, testing for mycoplasma contamination is a serious concern in the cell culturing process. Hence, to obtain better results and mitigate the risk, many pharmaceutical players have been providing solutions for testing mycoplasma contamination. The rise in the increasing need for testing mycoplasma contamination for research laboratories, commercial facilities, cell-derived biopharmaceutical products for medical use, and routine testing performed throughout the product manufacturing and development process is driving the patient of the global mycoplasma market.
Furthermore, suppose the mycoplasma contaminant is present in the final biological product. In that case, it can directly affect patient safety by potentially causing disease, loss of months of production time, loss of quality, and associated expenses & cost. Therefore, due to avoid batch loss, mycoplasma testing is important and leading the global market growth during the forecast period.
The mycoplasma testing market is likely to grow in the forecast period due to increased government initiatives & funding in research activities, R&D investments in life sciences, technological advancements, increasing growth opportunities provided by the biotechnology & pharmaceutical industry. Furthermore, factors such as increasing cell culture contamination with increasing demand for accurate, fast, and affordable testing drive the market for mycoplasma testing. Moreover, pharmaceutical outsourcing is one of the major factors that will foster the demand of the global mycoplasma market.
Based on product & services, the global mycoplasma market is classified into assays, kits & reagents, instruments, and services. The assays, kits & reagents segment assigned for the highest market share in 2019. It is attributable to the increasing adoption of assays & kits-based tests such as PCR, mycoplasma blood test, serology blood test, DNA test, and blood test for mycoplasma pneumonia in research activities.
The Instruments segment will garner a significant market share in the forecast period. It is owing to accurate, relatively quick, sensitive, and inexpensive.
Based on the application, the global mycoplasma market is segregated into Cell line testing, virus testing, end-of-production cell testing, and other applications. The cell line testing segment will garner higher market potential by 2027 due to the rise in contamination activities and increased adoption by the pharmaceutical & biotechnology industries for the research phase to clinical development and production of biopharmaceuticals.
The End of production cell testing segment will grow with a lucrative growth rate in the forecast period. It is due to Increasing activities such as selecting & testing cell lines and raw materials for the absence of undesirable microbes and viruses which may be infectious for humans.
Based on end-user, the global mycoplasma market is classified into pharmaceutical and biotechnology companies, contract research organizations, cell banks, and other end users. The pharmaceutical and biotechnology companies segment will garner higher market potential by 2027. Due to its widespread use in routinely testing for contamination throughout the manufacturing process through culture- or molecular-based detection methods that can help minimize economic risks & safety hazards.
The contract research organizations segment will be the fastest-growing segment in the forecast period due to increasing research services provided by these organizations and also increasing partnership between CROs & pharmaceutical companies contribute to increasing R&D activities.
The global mycoplasma market is segmented into North America, Europe, Asia Pacific, South America, and Middle East & Africa by geography.
North America is accounted for a fair share by 2027 in the mycoplasma market. The growth in the region can be attributed to the growing R&D sector and research activities.
The Asia Pacific is expected to provide significant growth opportunities due to rising investments made by government bodies and the surge in demand for drug production in the countries like India and China.
Companies such as Thermo Fisher Scientific Inc, Agilent Technologies Inc, Bionique® Testing Laboratories Inc, Minerva Biolabs, Charles River, SGS SA, Eurofins Scientific, Sartorius AG, F. Hoffmann-La Roche Ltd, Merck KGaA, and Lonza are the key players in the global mycoplasma market.
By Product & Services